TMCnet News

Suprax 2016-2017 U.S. Promotional Report - Research and Markets

[December 12, 2017]

Suprax 2016-2017 U.S. Promotional Report - Research and Markets

The "Suprax 2016 U.S. Promotional Report" report has been added to Research and Markets' offering.

The 5 Key Questions Addressed by this Report:

How many physicians were reached by Suprax through personal promotion in 2016 and how does this compare to its peer set in the Bacterial Infection and Ear Infection markets?
What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
How does Lupin's depth of coverage vary within key specialties (e.g., Pediatric Medicine, Family Medicine, and Internal Medicine) and how does this compare to its peers and the overallset of rep-accessible physicians?
How often are physicians receiving paid meals for Suprax throughout the year (e.g., monthly, quarterly, annually)?
Who were the most detailed prescribers and top paid speakers for Suprax in 2016?

Data Sources and Methodology:

We leverage company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available - covering payments to more than 900,000 U.S. healthcare professionals.
Over 2,000 paid interactions across 1,300 physicians made on behalf of Suprax were carefully examined to support our analysis. In addition, interaction data from 6 peer products (e.g., Ciprodex, Clindesse, Gynazole, Optiprio, Tindamax, and Uribel) was leveraged to provide benchmarking and market insights.